Abstract:Abstract Background Anti-nerve growth factor (NGF) monoclonal antibodies (anti-NGF mAbs) have been reported to significantly attenuate pain, but the mechanism involved has not been fully elucidated, and the serious adverse events associated with mAbs seriously limit their clinical use. This study further investigated the mechanism by which peripheral NGF is involved in neuropathic pain and found safe, natural compounds that target NGF to attenuate neuropathic pain. Methods Nociception was assessed by the Von Frey hair and Hargreaves’ methods. Western-blotting, qPCR and immunofluorescence were used to detect the cell signaling pathway. RAW264.7 macrophages and RSC96 Schwann cells were cultured for in vitro evaluation. Results Intraplantar administration of anti-NGF mAbs suppressed the expression of phosphorylated transforming growth factor-β-activated kinase 1 (TAK1) in the dorsal root ganglion (DRG) and sciatic nerve. Intraplantar administration of a TAK1 inhibitor attenuated CCI-induced neuropathic pain and suppressed the expression of phosphorylated mitogen-activated protein kinases (MAPKs) in the DRG and sciatic nerve. Perisciatic nerve administration of levo- corydalmine ( l- CDL) on the operated side obviously attenuated CCI-induced neuropathic pain and suppressed the expression of mNGF and proNGF. In addition, l -CDL-induced antinociception was reversed by intraplantar administration of NGF. Further results indicated that l- CDL-induced suppression of phosphorylated TAK1, MAPKs, and p65 and expression of the proinflammatory cytokines TNF-α and IL-1β in the DRG and sciatic nerve were all abolished by NGF. In addition, in vitro experiments indicated that l- CDL suppressed the secretion of NGF and proNGF in RAW264.7 macrophages and RSC96 Schwann cells, which was abolished by AP-1 and CREB agonists, respectively. Conclusions This study showed NGF inhibition suppressed TAK1 in the periphery to attenuate CCI-induced neuropathic pain through inhibition of downstream MAPK and p65 signaling. The natural compound l- CDL inhibited NGF secretion by macrophages and Schwann cells and downstream TAK1-MAPK/NF-κB signaling in the periphery to attenuate CCI-induced neuropathic pain. Graphical abstract Proposed mechanisms underlying the effect of l -CDL in periphery of CCI rats. In CCI rats, macropahages and Schwann cells could secret NGF to act on the receptors in the periphery to activate TAK1-MAPK/NF-κB axis and promote the release of proinflammatory cytokines, including TNF-α and IL-1β to promote neuropathic pain. l -CDL decreased the secretion of NGF through inhibiting AP-1 and CREB respectively in RAW264.7 and RSC96 Schwann cells to attenuate CCI-induced neuropathic pain by inhibiting the TAK1-p38 MAPK/NF-κB signaling pathway.

The Central Analgesic Mechanism of Ym-58483 in Attenuating Neuropathic Pain in Rats

Potent Analgesic Effects of a Store-Operated Calcium Channel Inhibitor.

Store-operated calcium entry mediates hyperalgesic responses during neuropathy

Effect of Spirocyclopiperazinium Salt Compound LXM-15 on Spinal Nerve Injury in Rats

Effect and Underlying Mechanisms of Spirocyclopiperazinium Salt Compound DXL-A-24 in Rats Following Spinal Nerve Ligation.

THE ANALGESIC EFFECTS OF INTRATHECAL ADMINISTRATION OF Ro 25-6981 ON NEUROPATHIC PAIN IN RATS:STUDY ON THE ELECTROPHYSIOLOGICAL MECHANISMS

Perturbing NR2B-PSD-95 interaction relieves neuropathic pain by inactivating CaMKII-CREB signaling.

SKF96365 Impedes Spinal Glutamatergic Transmission-Mediated Neuropathic Allodynia

Pharmacological Inhibition of CXCR2 Alleviates Neuropathic Pain by Inactivating Microglia in a Rat L5 Spinal Nerve Ligation Model.

INTRATHECAL MINOCYCLINE ON SPINAL NMDA RECEPTOR 1 SUBUNIT EXPRESSION IN RAT MODELS OF NEUROPATHIC PAIN

MrgC Agonism at Central Terminals of Primary Sensory Neurons Inhibits Neuropathic Pain

Activation of locus coeruleus-spinal cord noradrenergic neurons alleviates neuropathic pain in mice via reducing neuroinflammation from astrocytes and microglia in spinal dorsal horn

Ursolic Acid Molecules Dock MAPK1 to Modulate Gut Microbiota Diversity to Reduce Neuropathic Pain

MCRT, a Multifunctional Ligand of Opioid and Neuropeptide FF Receptors, Attenuates Neuropathic Pain in Spared Nerve Injury Model

Role of the Spinal Cord NR2B-containing NMDA Receptors in the Development of Neuropathic Pain

Elevated Expression and Activity of Sodium Leak Channel Contributes to Neuronal Sensitization of Inflammatory Pain in Rats

An Anti-Nociceptive Role for Ceftriaxone in Chronic Neuropathic Pain in Rats

Suppression of peripheral NGF attenuates neuropathic pain induced by chronic constriction injury through the TAK1-MAPK/NF-κB signaling pathways

Central Administration of C-X-C Chemokine Receptor Type 4 Antagonist Alleviates the Development and Maintenance of Peripheral Neuropathic Pain in Mice

The Utility of Peripherally Restricted Kappa-Opioid Receptor Agonists for Inhibiting Below-Level Pain after Spinal Cord Injury in Mice

CXCL12/CXCR4 signaling contributes to neuropathic pain via central sensitization mechanisms in a rat spinal nerve ligation model